Taking Mounjaro When Pregnant: the Clear Clinical Answer

You've just found out you're pregnant — and your Mounjaro pen is still in the fridge

This is a situation many women face before they have a chance to plan for it. The weight-loss journey, the weekly injections becoming routine, and then a positive test. The first thing to do is stop your next injection and call your GP or prescriber today, not after your next scheduled dose, not after the weekend. Same day.

Tirzepatide's licence covers weight management in adults who are not pregnant, and the NHS patient information for tirzepatide is direct: it should not be used during pregnancy. Animal reproductive toxicity studies have flagged fetal harm at doses that fall within the range humans are exposed to therapeutically. That doesn't tell us exactly what would happen in a human pregnancy, but it is precisely why regulators take the precautionary position they do.

If you have already missed a dose because of the pregnancy news, that is fine. Tirzepatide has a half-life of around five days and clears the body over a few weeks. What matters now is that your maternity team and your weight-management prescriber both know the medicine was part of your recent history. Your GP can coordinate that conversation, and a full review of your care plan should happen promptly. For more detail on how the medicine interacts with pregnancy-specific questions, our overview on Mounjaro and pregnancy covers the broader clinical picture.

What the evidence actually says, and what it doesn't

Human pregnancy data for tirzepatide are sparse. The clinical trial programme for Mounjaro enrolled adults with obesity and type 2 diabetes, and pregnant women were excluded, as they are from almost all phase-3 weight-loss trials. What we have instead is reproductive toxicity data from animal studies, reviewed by the MHRA as part of the licensing process, which showed embryo-fetal loss and reduced fetal weight at exposures overlapping with therapeutic human doses.

That absence of evidence is not reassurance. It means no one can responsibly say it is safe. The MHRA-approved Mounjaro Summary of Product Characteristics on the eMC reflects this directly: tirzepatide is contraindicated in pregnancy and should be discontinued at least one month before a planned conception, though your prescriber may advise a longer interval depending on your situation.

There is also an indirect effect worth understanding. GLP-1 receptor agonists reduce gastric motility and can affect the absorption of oral medicines taken at similar times. If you were also taking oral folic acid, that is another practical reason to tell your GP immediately so timing of supplementation can be reviewed. Questions about drinking alongside treatment are a separate but related concern you can read about in our guide to alcohol and Mounjaro, though pregnancy itself is the primary factor to address first.

Planning a pregnancy while on Mounjaro: the timeline question

If you are not yet pregnant but are planning to conceive, the guidance is clearer still: stop Mounjaro before you start trying. Many women asking whether they can use Mounjaro when pregnant are actually in this planning stage, and the SmPC advises stopping at least one month before attempting conception. Some prescribers recommend a longer interval, particularly for women who have been on higher maintenance doses, to allow any residual effects on gastric absorption to resolve and to give time to stabilise weight through dietary changes alone.

Weight management matters during pregnancy. Obesity is associated with increased risks of gestational diabetes, pre-eclampsia and other complications, as the NHS England guidance on weight-management medicines acknowledges in its broader discussion of these treatments. That makes the pre-conception period an important time to have a frank conversation with your GP about whether any support (dietetic input, physical activity guidance) can help maintain your weight in a healthy range while Mounjaro is paused.

Our prescribers regularly support women navigating exactly this transition. The consultation is free, and our clinical team can discuss the timing question with you directly. If your situation is more complex, our clinical lead can be involved in your review. You can also explore what weight-management options remain available after a planned pause by visiting our treatment consultation page.

After pregnancy: restarting Mounjaro and what comes next

Breastfeeding is the other half of this question. Tirzepatide is not recommended while breastfeeding. It is not known whether it passes into human breast milk in meaningful quantities, and given the fetal data, the precautionary approach is to avoid it. If you are wondering whether you can have Mounjaro when pregnant or shortly after birth, clinical guidance is to wait until breastfeeding has fully stopped before resuming treatment, and to discuss the timing with your prescriber rather than making that call independently.

Once breastfeeding has ended, restarting Mounjaro is a clinical decision that involves reassessing your eligibility, your current weight, and any changes in your health since you stopped. The same clinical framework applies as for any new patient: a prescriber reviews your consultation, checks your BMI, and assesses whether treatment remains appropriate. There is no auto-restart. Every repeat is reviewed, which is how it should be for a prescription-only medicine. If you have questions about cost context ahead of that restart, our page on the Eli Lilly UK price change explains what happened to Mounjaro pricing from late 2025 onward.

If you are unsure about your specific situation, the safest first step is always your GP or maternity team. For post-pregnancy weight management, our prescribers are available seven days a week. You can also read broader information about what tirzepatide is and how it works on our Mounjaro information page before your consultation. For anything about our service, our FAQs cover the most common practical questions.